OTP-01

PreclinicalSmall molecule

OOttimo Pharma Limited

OTP-01 is one of 15 small molecule programs targeting Advanced Solid Tumors. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumorsRecruiting

Advanced Solid TumorsPreclinical

Recruiting

Competition

Competitive Landscape

28 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 1

64 2

Paraplatin

AAvyxa

Phase 1

35 3

Beyfortus

BeiGene

Phase 1

11 4

Eloxatin

Teva

Phase 1

9 5

Erbitux

IImclone

Phase 1

19 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 1

7 7

Opdivo

Bristol-Myers Squibb

Preclinical

21 8

Alimta

GGynecologic Oncology Group

Phase 1

1 9

Yervoy

Bristol-Myers Squibb

Preclinical

8 10

5-Fluorouracil

Merck & Co.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Advanced Solid Tumors

NCT07266428

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

Recruiting·OOttimo Pharma Limited·Preclinical·NCT07266428·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OTP-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OTP-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OTP-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ottimo Pharma Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: OOttimo Pharma Limited

OTP-01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News